Utilities, Consumer...
Health Care: Drugs
Depomed Inc. (DEPO: NASDAQ)
$6.53 -0.40 | -5.77%
02/09/12 - 04:00 PM ET
739.13K / 549.10K
Vol / Avg. Vol:6.95 / 6.93
Open / Prev. Close:6.49 - 7.00
Today's Range:4.20 - 10.19
52 Wk Range:33.78%
Performance YTD:TheStreet Rating:
Portfolios with DEPO
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- Usertracking
- UserAccelerant
- UserRASHID 1
- UserPortfolio 02
- UserJan Jan Portfolio 1
- Contributor10 Surging Stocks Most at R...
- ProDeltec Asset Management LLC
- Usergbwineman Portfolio 1
- UserLTR7181 Portfolio 1
Latest DEPO Headlines from TheStreet
- Depomed: After-Hours Trading 02.03.12 | 05:02 pm
- Depomed Stock Hits New 52-Week Low (DEPO) 10.18.11 | 10:10 am
- Depomed Stock Gaps Down On Today's Open (DEPO) 10.14.11 | 09:10 am
- 7 Stocks to Watch: Google, Apple 10.14.11 | 07:10 am
- Google, Depomed: After-Hours Trading 10.13.11 | 05:10 pm
- Acadia Pharmaceuticals: Investing With No Safety Net 06.24.11 | 10:06 am
- Biotech Stock Mailbag: Star Scientific 03.18.11 | 07:03 am
- 5 Stocks to Watch: Sanmina, UBS 03.17.11 | 07:03 am
- Guess?, DepoMed: After-Hours Trading 03.16.11 | 05:03 pm
- Stock Wrap: The Real Story, March 15
03.15.11 | 04:03 pm
Press Releases for DEPO
- Santarus And Depomed Announce New U.S. Commercialization Agreement For GLUMETZA Prescription Products - Business Wire 08.22.11 | 05:08 am
- Ironwood Pharmaceuticals And Depomed Announce Collaboration, Research And License Agreement - Business Wire 07.27.11 | 04:07 pm
- Santarus And Depomed Announce Availability Of GLUMETZA 500 Mg Tablets - Business Wire 01.05.11 | 04:01 am
- New Clinical Study Shows Patients With Type 2 Diabetes May Be Able To Tolerate Higher Doses Of Metformin Using GLUMETZA - PR Newswire 06.28.10 | 08:06 am
- Depomed To Present At The 9th Annual JMP Securities Research Conference - Business Wire 05.04.10 | 08:05 am
- Depomed To Present At The Deutsche Bank 35th Annual Health Care Conference - Business Wire 04.29.10 | 04:04 pm
- Depomed Reports First Quarter 2010 Financial Results - Business Wire 04.29.10 | 04:04 pm
- Depomed To Announce First Quarter 2010 Financial Results On April 29, 2010 - Business Wire 04.22.10 | 08:04 am
- Depomed To Present At The BioCentury And Thomson Reuters Future Leaders In The Biotech Industry Conference - Business Wire 03.31.10 | 07:03 pm
- Depomed Announces Submission Of New Drug Application For Investigational Postherpetic Neuralgia Treatment DM-1796 - Business Wire 03.30.10 | 04:03 pm
Partner Headlines for DEPO
- Company News for February 7, 2012 - Corporate Summary - Zacks 02.07.12 | 10:02 am
- 7 Healthcare Stocks Undervalued By Earnings Growth And Cash Flows - Seeking Alpha 02.03.12 | 07:02 pm
- Depomed Announces FDA Approval of Merck's JANUMET XR That Accesses Depomed Patents Licensed to Merck - Benzinga 02.03.12 | 04:02 pm
- Depomed Receives Notice of Paragraph IV Certification Against Patents for Gralise - Benzinga 01.23.12 | 04:01 pm
- BMS Drug Deemed Too Costly: Weekly Round-Up Of Biotech Failures And Mishaps - Seeking Alpha 10.16.11 | 08:10 am
- UPDATE: Zacks Upgrades DepoMed from Neutral to Outperform - Benzinga 08.10.11 | 09:08 am
- 5 Highly Profitable Stocks Undervalued by EPS Trends - Seeking Alpha 07.11.11 | 06:07 am
- Contrarian Ideas: 25 High Growth Stocks With Significant Short Selling - Seeking Alpha 06.06.11 | 08:06 am
- DepoMed Reports EPS of $1.77 vs. $1.05 Estimate; Revenues $83.1M vs. $81.42M Estimate (DEPO) - Benzinga 05.05.11 | 04:05 pm
- DepoMed Ticks Higher After Positve Blog Post At SeekingAlpha (DEPO) - Benzinga 04.21.11 | 09:04 am
